A Phase 1/2a Study of the 2S,4R Enantiomer of Ketoconazole in Subjects With Type 2 Diabetes Mellitus

Completed · Phase 1/Phase 2

Conditions studied: Type 2 Diabetes

In brief

The study is designed to test the safety, tolerability of a newly developed form of ketoconazole (DIO-902) for the treatment of elevated blood sugars in type 2 diabetes. This study also will also examine the effect of the drug on total and LDL cholesterol and blood pressure. Elevated cortisol may contribute to the development of Type II diabetes. The investigational drug DIO-902 may reduce the level of cortisol in blood and therefore provide better control of blood sugar levels in patients with Type II diabetes.

Key facts

Study ID

NCT00302224

Run by

DiObex

People needed

50

Starts

2005-02-01

Expected to finish

2006-08-01

Last updated by the study team

2008-02-22

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female, age 18 to 70
• Females are non-lactating and using adequate contraception, in the opinion of the Principal Investigator and negative serum pregnancy test if of child bearing potential (intact uterus and pre-menopausal)
• Diagnosis of type 2 diabetes mellitus (DM) for at least 6 months. Type 2 diabetes may be untreated or may be treated with diet and exercise only and/or pharmacologic therapy as in Inclusion Criterion 4
• Pharmacologic treatment for type 2 DM may include the following and must be stable for > 3 months Glucophage (Metformin) (< maximum dose of 2550 mg) or Glucophage XR (< maximum dose of 2000 mg)
• HbA1C level of 6.5 to 10.9%
• Fasting C-peptide level of greater than or equal to 0.8 nmol/L (2.4 ng/mL)
• ACTH stimulation test results with any cortisol level (baseline, 30 or 60 minutes) of >18 µg/dL
• Normal thyroid stimulating hormone
• 12-lead electrocardiogram (ECG) shows no acute ischemia or clinically significant abnormality
• BMI of 26 to 40 kg/m2
• Subjects with a history of hypertension may be on a stable anti-hypertensive regimen (except those drugs stated under Exclusion Criterion 7) for > 2 months
• Ability to comprehend and a willingness to provide informed consent

You may not qualify if…

• History of any atherosclerotic disorder (myocardial infarction, angina, cerebrovascular accident, peripheral vascular disease or congestive heart failure secondary to ischemic myocardial injury) that would, in the estimation of the Investigator, make it unsafe to stop all lipid lowering drugs during the course of the study
• Known hypersensitivity or idiosyncratic reaction related to ketoconazole or other imidazole compounds
• History of malignancy (except basal cell carcinoma) within the 3 years before the initial dose of the study medication
• Excessive alcohol intake or drug abuse using the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV), criteria
• Any other clinically significant medical condition, as determined by the Investigator. These clinically significant medical conditions include proliferative diabetic retinopathy and neuropathic symptoms that limit activities of daily living
• Participation in another clinical trial and/or treatment received with any investigational agent within one month before the initial dose of study medication
• Concomitant therapy with the following: any antacid or ulcer medication, weight loss medications, oral or injected hypoglycemics (metformin is allowed) or insulin, steroids, cyclosporine, tacrolimus, midazolam, digoxin, coumarin derivatives, phenytoin, rifampin, loratadine, HIV protease inhibitors, spironolactone, thiazide diuretics, calcium channel blockers and erythromycin. Subjects taking lipid lowering medications may be enrolled if Investigator determines that subject does not have any conditions that preclude this cessation and subject is willing to stop such medications 21 days prior to Study Visit 1 through Study Visit 3 (Day 16)
• History of HIV
• Positive hepatitis B (HBsAg) or positive hepatitis C (Hepatitis C antibody) test during Screening
• WBC count <4000/µL or >14,000/µL
• Hemoglobin <12.0 gm/dL in females and <14.0 gm/dL in males
• Any single hepatic enzyme (ALT, AST, AP and total bilirubin) is greater than the upper limit of the normal reference range used by the central laboratory
• Creatinine > 1.5 times the upper limit of normal
• Known hypersensitivity to cosyntropin (ACTH) or any component of the formulation (mannitol or sodium chloride)

Where it is running

• Asha Thomas, MD - Medstar — Washington D.C., District of Columbia, United States
• Marc Rendell, MD - Creighton University — Omaha, Nebraska, United States
• Dr. Andrew Ahmann, MD - Radiant Research — Portland, Oregon, United States
• Carlos Arauz-Pacheco, MD - Radiant Research — Dallas, Texas, United States
• Sherwin Schwartz, MD - Diabetes and Glandular Disease Clinic — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.